217 reports of this reaction
1.5% of all CEFTAZIDIME reports
#18 most reported adverse reaction
APLASTIC ANAEMIA is the #18 most commonly reported adverse reaction for CEFTAZIDIME, manufactured by Hospira, Inc.. There are 217 FDA adverse event reports linking CEFTAZIDIME to APLASTIC ANAEMIA. This represents approximately 1.5% of all 14,861 adverse event reports for this drug.
Patients taking CEFTAZIDIME who experience aplastic anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APLASTIC ANAEMIA is a less commonly reported adverse event for CEFTAZIDIME, but still significant enough to appear in the safety profile.
In addition to aplastic anaemia, the following adverse reactions have been reported for CEFTAZIDIME:
The following drugs have also been linked to aplastic anaemia in FDA adverse event reports:
APLASTIC ANAEMIA has been reported as an adverse event in 217 FDA reports for CEFTAZIDIME. This does not prove causation, but indicates an association observed in post-market surveillance data.
APLASTIC ANAEMIA accounts for approximately 1.5% of all adverse event reports for CEFTAZIDIME, making it a notable side effect.
If you experience aplastic anaemia while taking CEFTAZIDIME, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.